title: Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas.
abstract: Neonatal hemangioma is a common benign proliferation of unorganized structures containing stromal and capillary endothelial cells. We tested the hypothesis that such cell proliferation might result from the release by stromal cells of endothelial cell mitogens. Stromal cells cultured from biopsies of surgically removed life-threatening hemangiomas released an endothelial cell mitogen in vitro that was indistinguishable from vascular endothelial growth factor (VEGF) based on independent criteria such as affinity chromatography for heparin or anti-VEGF IgG and radioreceptor assay. A functional product of the KDR gene encoding a cognate VEGF receptor was also expressed by these stromal cells. Transient transfection with antisense oligonucleotides targeted on the translation initiation codon of KDR abolished its tyrosine phosphorylation and mitogenic response of neonatal hemangioma cells to VEGF, confirming the existence of an autocrine loop of proliferation. When grafted in nude mice, these stromal cells elicited an angiogenic response that was blocked by neutralizing anti-VEGF IgG. These results might provide a clue to the importance of stromal cells in the pathogeny of neonatal hemangiomas.
authors.affiliation: Unité INSERM 353, Hopital Saint-Louis, Paris, UPR CNRS 9006, France.
authors.forename: M
authors.initials: M
authors.lastname: Berard
authors.forename: S
authors.initials: S
authors.lastname: Sordello
authors.forename: N
authors.initials: N
authors.lastname: Ortega
authors.forename: J L
authors.initials: JL
authors.lastname: Carrier
authors.forename: N
authors.initials: N
authors.lastname: Peyri
authors.forename: M
authors.initials: M
authors.lastname: Wassef
authors.forename: N
authors.initials: N
authors.lastname: Bertrand
authors.forename: O
authors.initials: O
authors.lastname: Enjolras
authors.forename: L
authors.initials: L
authors.lastname: Drouet
authors.forename: J
authors.initials: J
authors.lastname: Plouet
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D016228:Endothelial Growth Factors / Q000096:biosynthesis / Q000276:immunology / Q000494:pharmacology*; D005260:Female; D006391:Hemangioma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007231:Infant, Newborn; D008222:Lymphokines / Q000096:biosynthesis / Q000276:immunology / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000517:prevention & control; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000276:immunology; D017978:Receptors, Growth Factor / Q000096:biosynthesis / Q000276:immunology; D040262:Receptors, Vascular Endothelial Growth Factor; D017154:Stromal Cells / Q000187:drug effects / Q000473:pathology; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D019043:Vascular Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D016228:Endothelial Growth Factors; D007074:Immunoglobulin G; D008222:Lymphokines; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor